These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 24736006)

  • 21. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
    Sekimukai H; Iwata-Yoshikawa N; Fukushi S; Tani H; Kataoka M; Suzuki T; Hasegawa H; Niikura K; Arai K; Nagata N
    Microbiol Immunol; 2020 Jan; 64(1):33-51. PubMed ID: 31692019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV.
    Okba NMA; Widjaja I; van Dieren B; Aebischer A; van Amerongen G; de Waal L; Stittelaar KJ; Schipper D; Martina B; van den Brand JMA; Beer M; Bosch BJ; Haagmans BL
    Emerg Microbes Infect; 2020 Dec; 9(1):1080-1091. PubMed ID: 32471334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.
    Hashem AM; Algaissi A; Agrawal AS; Al-Amri SS; Alhabbab RY; Sohrab SS; S Almasoud A; Alharbi NK; Peng BH; Russell M; Li X; Tseng CK
    J Infect Dis; 2019 Oct; 220(10):1558-1567. PubMed ID: 30911758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
    Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
    J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
    Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas.
    Adney DR; Wang L; van Doremalen N; Shi W; Zhang Y; Kong WP; Miller MR; Bushmaker T; Scott D; de Wit E; Modjarrad K; Petrovsky N; Graham BS; Bowen RA; Munster VJ
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30832356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
    Chi H; Zheng X; Wang X; Wang C; Wang H; Gai W; Perlman S; Yang S; Zhao J; Xia X
    Vaccine; 2017 Apr; 35(16):2069-2075. PubMed ID: 28314561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice.
    Li E; Chi H; Huang P; Yan F; Zhang Y; Liu C; Wang Z; Li G; Zhang S; Mo R; Jin H; Wang H; Feng N; Wang J; Bi Y; Wang T; Sun W; Gao Y; Zhao Y; Yang S; Xia X
    Viruses; 2019 Aug; 11(9):. PubMed ID: 31470645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
    Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
    Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
    Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
    J Virol; 2018 May; 92(10):. PubMed ID: 29514901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.
    Agnihothram S; Gopal R; Yount BL; Donaldson EF; Menachery VD; Graham RL; Scobey TD; Gralinski LE; Denison MR; Zambon M; Baric RS
    J Infect Dis; 2014 Apr; 209(7):995-1006. PubMed ID: 24253287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.
    Almasaud A; Alharbi NK; Hashem AM
    Methods Mol Biol; 2020; 2099():117-126. PubMed ID: 31883092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.
    Choi J; Kim MG; Oh YK; Kim YB
    Expert Opin Ther Pat; 2017 Jun; 27(6):721-731. PubMed ID: 28121202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
    Volz A; Kupke A; Song F; Jany S; Fux R; Shams-Eldin H; Schmidt J; Becker C; Eickmann M; Becker S; Sutter G
    J Virol; 2015 Aug; 89(16):8651-6. PubMed ID: 26018172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of candidate vaccine approaches for MERS-CoV.
    Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
    Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.
    Ma C; Li Y; Wang L; Zhao G; Tao X; Tseng CT; Zhou Y; Du L; Jiang S
    Vaccine; 2014 Apr; 32(18):2100-8. PubMed ID: 24560617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Chen WH; Tao X; Agrawal AS; Algaissi A; Peng BH; Pollet J; Strych U; Bottazzi ME; Hotez PJ; Lustigman S; Du L; Jiang S; Tseng CK
    Vaccine; 2020 Nov; 38(47):7533-7541. PubMed ID: 33039209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
    Kato H; Takayama-Ito M; Iizuka-Shiota I; Fukushi S; Posadas-Herrera G; Horiya M; Satoh M; Yoshikawa T; Yamada S; Harada S; Fujii H; Shibamura M; Inagaki T; Morimoto K; Saijo M; Lim CK
    PLoS One; 2019; 14(10):e0223684. PubMed ID: 31589656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.